Compare CVS Health Corp (CVS) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Nutrien Ltd — how do they compare? CVS Health Corp trades at $86.2 (market cap $112.49B), while Nutrien Ltd trades at $69.9 (market cap $33.52B). The key difference: CVS Health Corp is far larger — about 3.4× Nutrien Ltd's market cap, and Nutrien Ltd pays the higher dividend (3.14%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Nutrien Ltd for 59 Days on average.
| CVS | NTR | |
|---|---|---|
Market Cap | $112.49B | $33.52B |
Volume | 8,467,392 | 1,154,412 |
Sector | Health | Basic Materials |
52-Week High | $110.60 | $83.94 |
52-Week Low | $70.08 | $53.64 |
Typical Hold Time | 83 Days | 59 Days |
Enterprise Value | $174.83B | $45.32B |
Dividend Yield | 3.02% | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
Nutrien (NTR) trades at $69.87, down 1.87% on the day, with mixed technical signals showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 earnings of $2.61 per share, missing estimates, while revenue benefited from higher fertilizer prices. Analyst consensus remains moderately bullish with a $76.14 price target, though recent news highlights industry headwinds from potential Belarus potash imports.
The stock presents a value opportunity with reasonable P/E (14.16) and P/B (1.29) ratios, supported by strong cash flow generation. However, investors face risks from volatile fertilizer markets, competitive pressures, and cyclical agricultural demand. Near-term performance will depend on Q3 earnings results and management's strategic update at the November Investor Day.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
